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The maintenance of tunneled catheter (TC) patency is critical for the provision of adequate hemodialysis in patients who are
TC-dependent. TC dysfunction results in the need for costly and inconvenient interventions, and reduced quality of life. Since
the introduction of TCs in the late 1980s, heparin catheter lock has been the standard prophylactic regimen for the prevention of
TC dysfunction. More recently, alternative catheter locking agents have emerged, and in some cases have shown to be superior
to heparin lock with respect to improving TC patency and reducing TC-associated infections. These include citrate, tissue
plasminogen activator, and a novel agent containing sodium citrate, methylene blue, methylparaben, and propylparaben. In
addition, prophylaxis using oral anticoagulants/antiplatelet agents, including warfarin, aspirin, ticlodipine, as well as the use of
modiﬁed heparin-coated catheters have also been studied for the prevention of TC dysfunction with variable results. The use of
oralanticoagulants and/orantiplatelet agentsasprimaryorsecondaryprevention ofTCdysfunctionmustbeweighed againsttheir
potential adverse eﬀects, and should be individualized for each patient.
1.Introduction
Tunneledcatheters(TCs)arefrequentlyusedinpatientswho
require both temporary and long-term hemodialysis (HD)
but do not have a functioning arteriovenous ﬁstula, graft, or
peritoneal dialysis catheter [1]. About 20% of prevalent and
80% of incident HD patients in the United States use a TC
and the proportion is even higher in some other countries
[2, 3]. TCs have advantages and disadvantages as a vascular
access for dialysis [1, 3, 4]. There is no need for a surgical
procedure to place a TC or waiting for maturation prior to
use. Thus, TCs are immediately available for use, and there
are several diﬀerent options on where to place them in most
patients. Unfortunately, TCs have several major problems
including frequent TC dysfunction and infections. Patients
with TC have more hospitalizations, incur higher costs,
and are at increased risk for inadequate dialysis and higher
morbidity and mortality [1–6]. The main objective of this
paper is to evaluate potential interventions to prevent HD
TC dysfunction. According to the NKF Dialysis Outcomes
QualityInitiative(KDOQI)-2006,dialysisaccessdysfunction
is deﬁned as an inability to achieve a dialysis blood ﬂow
rate of at least 300mL/min during the ﬁrst hour of dialysis
despiteatleastoneattempttoincreasebloodﬂow[1].Several
interventions including instillation of locking solutions and
administration of systemic anticoagulation and antiplatelet
agents are reviewed. Table 1 is a summary of the most
rigorouslypublishedclinicaltrialsofinterventionstoprevent
dialysis TC dysfunction [7–27].2 International Journal of Nephrology
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2. TC Insertion
Several investigators have reviewed the principles of TC
insertion [6, 28–30]. TC insertion should be performed
with ultrasound guidance to identify the vein and guide the
needle puncture [6, 31, 32]. The right internal jugular vein
is the preferred site as it oﬀers a more direct route to the
right atrium and usually allows a smooth wide curvature
to the TC [1, 6, 28, 29]. The use of ﬂuoroscopy is strongly
recommended to guide placement of the TC tip in the
midatrium [1, 28]. TCs in the left internal jugular vein have
a poorer blood ﬂow than in the right internal jugular vein.
TC in the subclavian vein can lead to subclavian vein stenosis
and prevent future use of the ipsilateral upper extremity for
a permanent vascular access [33]. Other sites such as femoral
veins are not recommended as sites for TC insertion given
the risks of infection and limitations to patient mobility.
3. The Role of Bioﬁlm and
Fibrin Sheath Formation in Hemodialysis
Catheter Dysfunction
A bioﬁlm is deﬁned as a microbially derived, sessile commu-
nity, characterized by cells that are attached to a substratum
ortoeachotherandareprotectedbyamatrixofextracellular
polymeric substances that they have produced [34]. One
major complication of bioﬁlms, in addition to infection, is
the development of a ﬁbrin sheath, which plays a major role
in TC dysfunction.
While the pathophysiology of bioﬁlm production is
unclear, it has been hypothesized that bioﬁlm formation
occurs after initial contact of free-ﬂoating bacteria with
a foreign surface, that is, dialysis TC, and can occur as
early as 1–14 days after placement [35–40]. The bacteria
initiallyattacheandadhereirreversiblytotheforeignsurface,
generate molecular signaling, and proliferate to transform
into bacterial microcolonies [35–37]. Subsequently, the
bacteria generate a coating of exopolysaccharide from the
bacterial products so that their progeny can adhere ﬁrmly
to the surface covered by a sticky glycocalyx matrix, called
the bioﬁlm, which envelopes the community of bacterial
microcolonies [35–37]. Bioﬁlms subsequently evolve and
mature into a community of bacteria covered by a dense
layer of matrix [35–37]. Furthermore, bacteria form bioﬁlms
preferentially in very-high-shear environments, similar to
conditions that occur within the TC during the dialysis
procedure, by enhancing bacterial adhesion [34]. Of note,
the mere presence of a bioﬁlm does not necessarily lead to
infection and it may grow too slowly to produce clinical
symptoms such as fever, chills and bacteremia. However, one
important noninfectious complication of bioﬁlm formation
is the concurrent development of a ﬁbrin sheath, which plays
a major role in TC dysfunction.
Since the pathogenesis of bioﬁlm development to ﬁbrin
sheath formation is not well understood, there is debate
as to the sequence of ﬁbrin sheath formation, bioﬁlm
development, and their interdependency [41]. However, the
best evidence supports the hypothesis that a bioﬁlm evolves
over days to months into a more complex structure, a
ﬁbrin sheath. In addition to ﬁbrin, these sheaths contain
multipleothermolecularandcellularcomponents,including
laminin, ﬁbronectin, collagen, and smooth muscle cells,
overlyingendothelialcells[35].Theseﬁndingsdemonstrated
that the TC-related ﬁbrin sheath is an active response of
the components of the vessel wall to the TC (e.g., bioﬁlm
formation) and associated thrombosis, as opposed to a mere
deposition of acellular material and thrombus [42]. The
ﬁbrin sheath initiates at the point of contact between the TC
andthevesselwall,advancesalongtheentirelengthoftheTC
or device, and can create a one-way valve mechanism, with
resultant decrease in the TC ﬂow [42]. Fibrin sheaths play
a major role in TC malfunction [35, 43–45]. Although the
reported incidence of ﬁbrin sheath can be as high as 100%,
this condition may remain subclinical. However, in clinically
aﬀected (symptomatic) patients, the ﬁbrin sheath may result
in thrombus formation and malfunctioning TCs, in addition
to infection [42, 43].
Once bioﬁlms form, they are very resistant to antithrom-
botic and antimicrobial agents. There have been several
recent clinical studies that have focused on investigating
prophylactic pharmacologic treatment with antithrombotic
and antimicrobial locking solutions and biological charac-
teristics of bacterial TC adherence and bioﬁlm formation
showing some promising results [46, 47].As with the paucity
of therapies to prevent bioﬁlm development, there are also
few proven therapies to prevent ﬁbrin sheath formation.
The current treatment paradigms for management of ﬁbrin
sheaths in dysfunctional TCs include thrombolytic therapy,
angioplasty with ﬁbrin sheath disruption, and TC exchange
[1, 42]. Transfemoral percutaneous ﬁbrin sheath stripping is
associated with poor patency. The best management strategy
for TC malfunction is its prevention. The most common
form of prevention is with the use of anticoagulant locking
during the intradialytic period.
4.HeparinCatheterLock
Heparin lock has been used for decades with relative safety;
however, TC dysfunction continues to remain problematic.
The rate of TC thrombosis associated with heparin lock
in several large series ranges between 4–5.5 episodes/1000
days, and the rate of TC loss due to dysfunction is 1.8–
3.6/1000 days [7–12]. The concentration of heparin used
as a TC locking solution varies among studies, ranging
between 1,000U/mL and 10,000U/mL. In a prospective trial
comparing a period of high dose (10,000U/mL) versus a
period of low dose (1,000U/mL) heparin lock, there was no
signiﬁcant diﬀerence in TC dysfunction or bleeding com-
plications between heparin lock concentrations, although
the need for TPA therapy was 4-fold higher (P<0.001)
when low-dose heparin lock was utilized [7]. Similar results
were reported in a smaller, retrospective study comparing
TPA administration in 2HD units, one unit using high-
dose heparin lock (10,000U/mL) and the other using low-
dose heparin lock (1,000U/mL) [8]. Low-dose heparin lock
was associated with 2-fold increase in TPA administration6 International Journal of Nephrology
(P<0.001). Theoretically, the use of high-concentration
heparin lock may be advantageous in reducing both TPA-
related costs and delay in treatment initiation; however,
when Holley and Bailey took into account the diﬀeren-
tial cost/treatment between low- and high-dose heparin
lock ($0.20 versus $2.67), low dose heparin resulted in
signiﬁcant savings despite higher TPA use [8]. Low-dose
heparin lock (1000U/mL) is particularly advantageous in
the immediate postinsertion period [21]. In a retrospective
analysiscomparingheparinlock(5000U/mL)versusheparin
lock (1000U/mL) or citrate administered immediately after
TC insertion, patients receiving high-dose heparin lock
(5000U/mL) had a 9-fold increase in composite bleeding
events (P = 0.01), and 7.7% experienced a major bleeding
event (versus 0% in the low-dose heparin or citrate group)
[48]. A signiﬁcant increase in severe hemorrhage after TC
insertion was associated with heparin lock (5,000U/mL) in
a large randomized controlled trial in comparison to citrate
30% lock, (rate of severe hemorrhagic events: heparin 13%
versus citrate 4%, P = 0.005) [15].
The optimal volume of heparin lock should be individ-
ualized according to the patient and catheter characteristics.
AlldialysisTCshavesomedegreeoflockingsolutionleakage,
depending on their design, even when <20% of the TC lock
volume is instilled [49]. TC leak begins immediately after
instillation and continues over a 30-minute period, and is
higher in nontunneled catheters for both periods [50, 51].
The excess leakage volume is 0.16–0.48mL with <20% TC
ﬁll volume, and 0.99–1.43mL with >20% TC ﬁll volume. TC
lock overﬁll by 20% has been suggested to ensure delivery
of heparin to the TC tip and wall and to improve TC
patency which may be desirable in TCs with a history of
recurrent thrombosis. Overﬁll by 20%, however, may result
in the inadvertent systemic administration of substantial
amounts of heparin and may be problematic in the pre-
operative patient, or in patients with bleeding diatheses [49,
52]. Undesired systemic anticoagulation (increased activated
partial thromboplastin time), caused by heparin lock overﬁll
m a yp e r s i s tf o ru pt o4h o u r s[ 53]. The average rate of major
bleeding episodes associated with heparin lock (5,000U/mL)
is approximately 2/1000 TC days [15].
Heparin lock has been traditionally administered in a
thrice weekly dosing, with an interdialytic heparin dwell
period. The results of a recently published small prospective
s t u d yr e p o r t e di m p r o v e de ﬃcacy using a 6-day per week
heparin locking regimen. This protocol is not practical in
an outpatient HD setting, but may be useful in hospitalized
patients with HD TCs. One caveat to this protocol, however,
isthatmorefrequentaccessoftheTClumenhasthepotential
to increase the risk of infectious contamination if not using
sterile procedures [54].
5. TrisodiumCitrateLock
In the last decade, trisodium citrate has emerged as an
alternative to heparin as a TC locking solution. Seven clinical
trials reported citrate lock (4%, 30%, or 46.7%) to be equiv-
alent or superior to heparin lock (5,000–10,000U/mL) with
respect to the thrombolytic therapy rates and number of TCs
removed for ﬂow problems (Table 1 [6, 9–12]). In contrast,
2 studies reported unfavorable outcomes with citrate lock.
The ﬁrst was a small study (19 TCs) comparing citrate 5% to
heparin (5000U/mL) [13] .T h er a t eo ft h r o m b u sa s p i r a t e d
from the TC was doubled with citrate (14% versus 7%,
P<0.001); however, the rate of thrombolytic therapy was
not signiﬁcantly diﬀerent (P = NS). In a larger (n = 232)
recently published randomized controled trial comparing
46.7% citrate lock versus heparin lock (5,000U/mL), the
need for thrombolytic therapy was greater in the citrate
group (8.2 versus 4.3/1000 days, P<0.001) [17]. One
advantage of citrate lock is that the bleeding event rate is
reported to be signiﬁcantly lower. In the ﬁrst study, which
includedbothtunneled(n = 98)andnontunneled(n = 193)
HD catheters in acute and chronic renal failure patients,
citrate lock (30%) was associated with a 70% reduction
in major bleeding events when compared to heparin lock
(5,000U/mL), (P = 0.01) [15]. In the second study of 61
patientswithHDTCs,thereweresigniﬁcantlyfewersystemic
bleedingeventsusing4%citratelock(7in32patients)versus
heparin lock (5,000U/mL) (21 in 29 patients) (P = 0.035)
[12].
Citrate and other chelating agents have been shown, in
vitro, to inhibit bioﬁlm formation and growth of Staphy-
lococcus aureus and Staphylococcus epidermidis at concen-
trations greater than 0.5%. In contrast, heparin stimulated
bioﬁlm formation in this study [55]. Clinical trials using 4%
citrate lock have not shown to lower TC-related bacteremia
(CRB) rates, with the exception of one study [10]. In a
prospective, nonrandomized trial, a signiﬁcant reduction
in CRB rates was observed when the TC locking protocol
changedfromatimeperiodusingheparinlocktoaperiodof
citrate lock 4% use; however, these ﬁndings are confounded
by the concurrent initiation of a topical polyantibiotic
ointment protocol, applied to the TC exit site, during the
study period [10]. In two other studies comparing 4% citrate
to heparin, there was no signiﬁcant diﬀerence in CRB rates
between locking agents [11, 12]. The ability of citrate to
inhibit bioﬁlm formation and bacterial growth is highly
concentration dependent. In an in vivo study, Ash et al.
observed a reduction in CRB when concentrations of 23%
citrate or higher were used as a HD TC locking solution
[56]. In a large randomized controlled trial, 30% citrate
lock was associated with a signiﬁcant reduction in the CRB
rate (1.1 versus 4.1/1000 TC-days, P<0.001) and fewer
admissions for TC-related infections (0.7 versus 2.7 per 1000
TC days) [15]. More recently, a randomized controlled trial
by Power et al. using 46.7% citrate lock versus heparin
lock (5000U/mL), failed to show a diﬀerence in CRB rates;
however, the CRB rate was lower than that reported in other
series (0.7/1000 TC days), which may have resulted in under-
powering this study [17].
An additional potential advantage of 4% citrate lock is
the estimated cost savings calculated in 2 Canadian studies.
An 80–85% reduction in costs was calculated using citrate
in comparison to heparin [10, 11]. In a 2008 position
paper by the American Society of Diagnostic Interventional
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heparin lock 1000U/mL or 4% citrate lock be used in
most TCs and that the injected volume not exceed the
internal TC volume [57]. There are, however, advantages to
citrate lock that make it a more desirable option, including
lower bleeding risk, possible reduction in bioﬁlm formation,
avoidance of HAAb formation, lack of interference with
prothrombin assays, and lower cost. At the present time, 4%
citrate is used in the majority of Canadian HD units where
it is available as a preﬁlled syringe (5mL). (Citralok, MED-
XL, Montreal, QC, Canada) In the United States 4% citrate
is currently available in larger volume bags (250–500mls)
requiring preparation by the HD unit staﬀ.
5.1. Novel Catheter Locking Solutions. Recently, Maki et
al. reported the results of a multicentered, randomized,
controlled trial using a novel catheter lock solution con-
taining sodium citrate, methylene blue, methylparaben, and
propylparaben (C-MB-P) in comparison to heparin catheter
lock for HD TCs. The use of the C-MB-P solution was
associated with a lower incidence of TC loss due to patency
failure (0 versus 4, P = 0.04) and a lower rate of TC-related
bacteremia (RR 0.29; CI 0.12–0.70; P = 0.005) [58].
6. Thrombolytic Agents asCatheter
LockingSolutions
Fibrinolytic agents have been studied as an alternative to
heparin for use as a TC locking solution. The potential
advantage of these agents is the prevention of TC-related
infections and improved TC patency. In a meta-analysis of
5 randomized controlled trials in 991 cancer patients using
TCs for chemotherapy, urokinaselock or ﬂush was associated
withasigniﬁcantreductioninTC-relatedinfection(HR0.77,
95%CI0.60–0.98,P = 0.01)[59].Invitro,alteplasehasbeen
shown to modestly inhibit Staphylococcus aureus bioﬁlm
formation in concentrations ≥0.5mg/mL [55]. Prevention
of HD TC thrombosis using a tissue plasminogen activator
(TPA) interdialytic lock was ﬁrst evaluated in 2 small clinical
studies. In comparison to alteplase lock (1mg/mL), heparin
lock (5000U/mL) was associated with more frequent throm-
boses (O.R. 2.4, 95% CI 1.5–4.0; P = 0.001). Schenk et al.,
using a prospective randomized crossover design, evaluated
the eﬃcacy of TPA lock versus heparin lock (1000U/mL) in
12 HD TCs [18]. TPA lock was associated with signiﬁcantly
improved blood ﬂow rates, lower venous pressures, and
fewer complications. In contrast, TC thrombosis, requiring
ﬁbrinolytic intervention, occurred in 20% of patients during
the heparin period. There was no diﬀerence in bleeding
or infectious events between the groups. The “Pre-CLOT”
(Prevention of Catheter Lumen Occlusion with r-TPA versus
heparin) randomly assigned 225 patients with a newly
inserted TC to heparin (5000U per milliliter) three times per
week or recombinant tissue plasminogen activator (rt-PA)
(1mg in each lumen) substituted for heparin at the midweek
session (with heparin used in the other two sessions) [20].
TC malfunction occurred in 40 of the 115 patients assigned
to heparin only (34.8%) and 22 of the 110 patients assigned
tort-PA(20.0%)(hazardratio,1.91;95%conﬁdenceinterval
( C I ) ,1 . 1 3t o3 . 2 2 ;P = 0.02). Catheter-related bacteremia
occurred in 15 patients (13.0%) assigned to heparin only, as
compared with 5 (4.5%) assigned to rt-PA (corresponding to
1.37 and 0.40 episodes per 1000 patient-days in the heparin
and rt-PA groups, resp.; P = 0.02). The risk of bacteremia
from any cause was higher in the heparin group than in the
rt-PA group by a factor of 3 (hazard ratio, 3.30; 95% CI,
1.18 to 9.22; P = 0.02). The risk of adverse events, including
bleeding,wassimilarinthetwogroups.Theincrementalcost
of caring for patients with rt-PA as compared with heparin
was $1,173 per patient (Canadian dollars).
7. Oral Agents for Prophylaxisto Inhibit
Catheter Dysfunction
The use of warfarin alone or in combination with an
antiplatelet agent has been evaluated for primary prevention
of HD TC dysfunction in 3 randomized controlled trials.
The ﬁrst study was a randomized placebo controlled trial
which included 85 HD patients receiving their ﬁrst TC
and compared ﬁxed dose warfarin (1mg/day) to placebo
[23]. This minidose of warfarin was previously shown to
be associated with a 75% reduction in TC thrombosis rates
in cancer patients [60]. Unfortunately, minidose warfarin
was not associated with improvement in primary unassisted
patency or assisted TC survival in HD TCs. There was
no increase in bleeding events with mini-dose coumadin.
Another important ﬁnding of this study was that an INR
of <1.00 was associated with signiﬁcantly greater risk of
TC loss due to dysfunction (HR = 4.0, 95% C.I. 1.1–14.5;
P = 0.04) and earlier need for thrombolytic therapy (H.R
2.8, 95% CI 1.3–6.1, P = 0.009) [17]. The second study
comparedlow-intensitymonitoredwarfarin(targetINR1.5–
1.9) to placebo in HD patients with newly placed TCs
[24]. Warfarin was ineﬀective in preventing TC dysfunction.
The third study included 144 newly inserted HD TCs,
compared low-intensity warfarin (targeted to an INR of
1.8–2.5) and ticlodipine (250mg/day) initiated within 12
hours after TC insertion (primary prevention) to a control
group (ticlodipine alone) who received warfarin after the
ﬁrst thrombosis (secondary prevention) [27]. There was a
signiﬁcant reduction in TC thrombosis/dysfunction when
the combined regimen of warfarin and ticlodipine was used
as primary prevention compared to secondary prevention
(0.16 versus 1.65 thrombotic events/patient year, P<0.001),
improvement in TC ﬂow rates, and fewer TC removals for
dysfunction (2.4% versus 17.5%, P<0.001). It should
be noted, however, that more patients in the primary
prevention group achieved adequate anticoagulation than
in the secondary prevention group (92% versus 65%, P<
0.05). There were no bleeding events associated with the
warfarin/ticlodipine combination.
Warfarinuseforsecondarypreventionwasalsoevaluated
by Zellweger et al. in a prospective study of 35 HD patients
considered high risk for TC dysfunction given low-intensity
warfarin (INR 1.5–2.0) compared to low-risk TC patients
[25]. Therapeutic warfarin with adequate anticoagulation
was associated with improved dysfunction-free TC survival8 International Journal of Nephrology
at 9 months (47.1%) in comparison to that with inadequate
anticoagulation (8.1%) (P = 0.0 1 ) .I na no b s e r v a t i o n a l
study by Obialo et al., 63 HD patients with TCs who were
already receiving chronic aspirin (n = 21, A, 325mg/day)
or therapeutic warfarin (n = 11, W, target INR 2-3)
therapy for an underlying cardiovascular indication, and
controls (n = 31, C) not taking either medication were
prospectively monitored [26]. Both aspirin and warfarin
were associated with improved primary TC patency at
120 days in comparison controls (C) (A 91%, W 73%, C
29% (P<0.001)). Gastrointestinal bleeding rates were
signiﬁcantly higher in those patients on aspirin and warfarin
in comparison to controls (A 24%, W 18%, C 0%, P<0.02),
and elderly patients were at highest risk of bleeding (H.R.
1.14, 95% C.I. 1.0–1.3, P = 0.008).
In summary, the combination of low-intensity warfarin,
to achieve a target INR of 1.5–2.0, with or without ticlodip-
ine, has not been consistently shown to be eﬃcacious in
maintaining HD TC patency, particularly when used as
primary prevention. Although this therapeutic combination
was not associated with an increased bleeding risk in the
trial by Col` I et al., low-intensity warfarin was associated
with a signiﬁcant bleeding risk in HD patients when
used for the prevention of TC [24] or arteriovenous graft
thrombosis [61]. In this study, by Crowther et al., warfarin
was associated with 6 major bleeding events (all patients
were also on aspirin), whereas none in the placebo group
had major bleeds (P = 0.03). Furthermore, warfarin had
no eﬀect on arteriovenous graft survival. The use of warfarin
should be reserved for high-risk patients with recurrent TC
dysfunction, using a low-intensity protocol (target INR of
1.5–2.0).
8.Heparin-CoatedCatheters
Heparin-coated HD TCs (HCC) have not been shown to
reduce the need for thrombolytic therapy or improve TC
survival in 2 retrospective trials [21, 22]. However, in one
of the studies, Jain et al. reported a signiﬁcantly lower TC-
associated bacteremia rate in the HCC group (34% HCC
versus 60% noncoated HD TCs, P<0.001) [22]. In the
second study, Clark et al. found no diﬀerence in infection
between HCC and noncoated HD TCs; however, the mean
observation period was relatively brief; (48–74 days) [21].
9. Conclusion
TCs remain uniquely vital to provide not only short-
term renal replacement therapy but also long-term HD
to thousands of patients every day. TC malfunction and
infections are the two most important complications from
TC and are responsible for higher morbidity and mortality
in many dialysis patients. Recent studies have elucidated the
importance of bacteria in the formation of bioﬁlms and
the development of ﬁbrin sheaths that play a major role
in the development of TC malfunction and TC-associated
infections.
Most eﬀorts to prevent dialysis TC malfunction have
focused on the instillation of locking solutions in TCs.
Heparin and citrate prevent clot formation in dialysis
TCs and are the most commonly used TC lock solutions.
Thrombolytic agents have been recently shown to be more
eﬀective in reducing TC-related infections and improving
TC patency. Systemic administration of oral anticoagulation
could be of beneﬁt in selected patients at high risk for
recurrent TC dysfunction, but is associated with greater
bleeding risk. The role of antiplatelet agents for prevention
of TC dysfunction has not been deﬁned.
10. FutureDirections
Important areas of future research include development of
modiﬁed TCs with new designs and thrombosis-resistant
properties and novel locking solutions and interventions
t op r e v e n to rr e d u c eb i o ﬁ l ma n dﬁ b r i ns h e a t hf o r m a t i o n .
Furthermore, attaining a better understanding of the patho-
genesis of bioﬁlm and ﬁbrin sheath development may allow
for the development of novel therapies to manage these enti-
ties through translational research. Thus, other additional
future areas of research could focus on (1) the molecular
and genetic basis of bioﬁlm and ﬁbrin sheath development,
(2) therapeutic agents that target the bioﬁlm phenotype
and community signaling-based agents that prevent the
formation, or promote the detachment, of bioﬁlms, and (3)
whether a blood-based biomarker could be associated with
the conversion from bacteria colonization into infection and
ﬁbrin sheath development [35, 47].
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